Excision repair cross complementing-group 1: gene expression and platinum resistance.
about
A Significant Statistical Advancement on the Predictive Values of ERCC1 Polymorphisms for Clinical Outcomes of Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer: An Updated Meta-AnalysisClinical significance of ERCC1, RRM1 and TS in non-small cell lung cancerPrognostic value of ERCC1 mRNA expression in non-small cell lung cancer, breast cancer, and gastric cancer in patients from Southern ChinaMolecular mode of action and role of TP53 in the sensitivity to the novel epothilone sagopilone (ZK-EPO) in A549 non-small cell lung cancer cellsCommercial laboratory testing of excision repair cross-complementation group 1 expression in non-small cell lung cancerExpression of excision repair cross-complementation group 1 and class III β-tubulin in thymic carcinoma.Prognostic significance of ERCC1 expression in postoperative patients with gastric cancer.Genetic variation in glutathione metabolism and DNA repair genes predicts survival of small-cell lung cancer patientsIs there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma?Thymidylate synthase and thymidine phosphorylase mRNA expression in primary lesions using laser capture microdissection is useful for prediction of the efficacy of FOLFOX treatment in colorectal cancer patients with liver metastasis.Using protein microarray technology to screen anti-ERCC1 monoclonal antibodies for specificity and applications in pathologyDifferential contributory roles of nucleotide excision and homologous recombination repair for enhancing cisplatin sensitivity in human ovarian cancer cellsThe expression of ribonucleotide reductase M2 in the carcinogenesis of uterine cervix and its relationship with clinicopathological characteristics and prognosis of cancer patients.Oxaliplatin: pre-clinical perspectives on the mechanisms of action, response and resistance.Molecular Markers with Predictive and Prognostic Relevance in Lung CancerDrug resistance and its significance for treatment decisions in non-small-cell lung cancer.CITED2 silencing sensitizes cancer cells to cisplatin by inhibiting p53 trans-activation and chromatin relaxation on the ERCC1 DNA repair gene.Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study.KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients.Fucoxanthin enhances cisplatin-induced cytotoxicity via NFκB-mediated pathway and downregulates DNA repair gene expression in human hepatoma HepG2 cells.Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer.Emodin regulating excision repair cross-complementation group 1 through fibroblast growth factor receptor 2 signaling.High ERCC1 expression is associated with platinum-resistance, but not survival in patients with epithelial ovarian cancerThe potential role of pharmacogenomic and genomic in the adjuvant treatment of early stage non small cell lung cancerERCC1 expression affects outcome in metastatic pancreatic carcinoma treated with FOLFIRINOX: A single institution analysis.Reactive Oxygen Species Modulator 1 (Romo1) Predicts Poor Outcomes in Advanced Non-small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy.Expression of Drug-Resistant Factor Genes in Hepatocellular Carcinoma Patients Undergoing Chemotherapy with Platinum Complex by Arterial InfusionDexamethasone induces docetaxel and cisplatin resistance partially through up-regulating Krüppel-like factor 5 in triple-negative breast cancer.The continuing role of chemotherapy for advanced non-small cell lung cancer in the targeted therapy era.Prognostic and predictive biomarkers in early stage non-small cell lung cancer: tumor based approaches including gene signaturesSynergistic antitumor effects of combined deguelin and cisplatin treatment in gastric cancer cellsDisseminated carcinomatosis of the bone marrow with disseminated intravascular coagulation as the first symptom of recurrent rectal cancer successfully treated with chemotherapy: A case report and review of the literatureEvaluation of effects of thymidylate synthase and excision repair cross-complementing 1 polymorphisms on chemotherapy outcome in patients with gastrointestinal tumors using peripheral venous blood.Excision Repair Cross-Complementation Group 1 Enzyme as a Molecular Determinant of Responsiveness to Platinum-Based Chemotherapy for non Small-Cell Lung Cancer.Gene expression and effects of orally active derivatives of fluoropyrimidine on gastric and colorectal cancer.Biological evaluation of transdichloridoplatinum(II) complexes with 3- and 4-acetylpyridine in comparison to cisplatin.The Challenges of Validating in Precision Medicine: The Case of Excision Repair Cross-Complement Group 1 Diagnostic Testing.ERCC1 expression status predicts the response and survival of patients with metastatic or recurrent cervical cancer treated via platinum-based chemotherapy.Effect of RAD51C expression on the chemosensitivity of Eμ-Myc p19Arf-/- cells and its clinical significance in breast cancer.The relationship between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase, excision repair cross-complementation group 1 and class III β-tubulin, and the therapeutic effect of S-1 or carbopla
P2860
Q26750858-6E1D1B35-8E70-41D6-AB8F-9E102B07C3E9Q26830488-16633DC0-510D-4985-81FB-CD08152B79A6Q26865990-43733058-D3DC-4C7C-B55B-05E7C8231A93Q28477992-5A2D1E1E-1E40-4615-A41E-23EC4132E657Q33577811-3FB6DA07-FED3-4CE6-94E6-E408D5985990Q33685172-29ADCCA9-F15E-4FFF-BFDA-FC662A7424E8Q33827385-C77B415A-8767-47A9-8F26-93E2BE2AE923Q34160556-36694574-A7F3-4F3E-B982-CE9D9637438BQ34205171-B16C7D84-1E5F-4DD3-8AA8-616C892C07C0Q34333072-DA6DFB7D-FC3B-4D5B-A429-DE87626012DCQ34484477-865D5360-CD65-49CF-9BE5-E7B9ABB4F918Q34722650-477A3BEB-01AC-4944-9625-BF17976E3573Q35123132-58CBB0AA-8E03-436E-A432-33202C758ACFQ35572923-69982164-9E7C-4459-BD56-4FEF8A2EC971Q35763239-A8E84317-8320-4575-BB20-91A4009B9368Q36040613-AE5AF1DA-FBA9-4FB0-B994-7C84AFDFE1A1Q36370912-E8986C0B-DB66-4313-B0C0-7D1C43EF25D7Q36557333-6969A4E0-6600-4410-AED2-01A5C411FE2FQ36557853-B47AD5A4-4FA0-45B5-A79D-80E4B91A0C0CQ36586981-9E1DAF37-0473-4336-8CE9-CFDE576183C9Q36817080-2D3C2287-26D8-4FE9-9CAC-C43F566D6530Q36821624-23F1920E-296E-475C-AB86-374524BAF339Q37108536-D19EE4D1-9284-4309-89C6-ACFDCD3F3BDDQ37194315-2CC8F70B-DAA6-4179-BD32-0953CF7BABC5Q37376487-EDA00FEB-B181-46BC-9C10-256D2A94937AQ37606687-F20F0F8E-F86D-444C-91C1-B32910F3C49DQ37666690-69E21F24-BC8E-46D0-9D4C-6B67A54427D6Q37706950-E07EAC49-2764-46B4-821A-EC5F1E184D9BQ38155855-9ABAC14C-4A26-473F-9BE5-70D38BC8C2A5Q38390072-03C405FA-BD35-4929-936C-C81B71891A02Q38958264-9D8CFF4D-0296-4852-9CF4-A4FE1E85DD3FQ39362738-0F564D3F-2AC7-4300-BDC9-5286363C02E8Q40492876-1A5DF036-FC91-450B-B8C2-A16E59274857Q41900593-07789748-3940-421D-B181-38EFE14C94D7Q42057665-E5D761C6-97BE-446F-9A91-D832FA5B4611Q42925820-F24272F6-5CAE-40E6-848D-5595F465D058Q47110861-CF4800B8-3954-450A-98CE-67741DE11769Q49270138-ABF129F6-CFD9-4E26-B3F5-3A68484F909CQ54948516-88FFC3E1-06DA-4267-8890-E1A753D225D4Q55439654-4D1EE350-6CA0-4C26-BFCF-F4F1FB9F9D56
P2860
Excision repair cross complementing-group 1: gene expression and platinum resistance.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Excision repair cross complementing-group 1: gene expression and platinum resistance.
@ast
Excision repair cross complementing-group 1: gene expression and platinum resistance.
@en
type
label
Excision repair cross complementing-group 1: gene expression and platinum resistance.
@ast
Excision repair cross complementing-group 1: gene expression and platinum resistance.
@en
prefLabel
Excision repair cross complementing-group 1: gene expression and platinum resistance.
@ast
Excision repair cross complementing-group 1: gene expression and platinum resistance.
@en
P2093
P1476
Excision repair cross complementing-group 1: gene expression and platinum resistance
@en
P2093
Eddie Reed
Jing Jie Yu
Ramin Altaha
Xiaobing Liang
P304
P577
2004-12-01T00:00:00Z